肠道益生菌对非酒精性脂肪肝的影响

目的探讨肠道菌群与非酒精性脂肪肝(NAFLD)的关系。方法对53例服用肠道益生菌的NAFLD患者和56例对照组患者进行服药前后肝脏的超声检查,抽血查血肌酐、尿素氮、总胆固醇、三酰甘油、空腹血糖,并同时对年龄和体质量指数(BMI)进行统计。结果服药前两组各项指标比较,差异无统计学意义(P0.05)。服药后肠道益生菌组和对照组比较,脂肪肝消退数明显增加,差异有统计学意义(P0.05)。服药前后两组比较,肠道益生菌组服药后较服药前脂肪肝消退数明显增加,差异有统计学意义(P0.01);而对照组各项指标比较,差异均无统计学意义(P0.05)。两组服药前后各种观察指标差值的比较,脂肪肝消退、中度脂肪肝减少数、总胆固醇、三酰甘油和尿素氮下降在肠道益生菌组差异有统计学意义(P0.05、P0.01)。结论口服益生菌可以降低NAFLD的发生,益生菌可能具有预防和治疗NAFLD的作用。

The influence of probiotics medications on nonalcoholic fatty liver disease

Objective To explore the influence of gut probiotics medications on nonalcoholic fatty liver disease （NAFLD）. Methods The live ultrasonic examination, plasma creatinine concentration, blood urinary nitrogen, total plasma cholesterol, plasma triglyceride, fasting blood glucose, age and body mass index （BMI） were observed in 53 eases of NAFLD patients medicated by gut probiotics for three months and 56 cases of control patients. Results The NAFLD was significantly decreased after gut probiotics medications compare with the control group and the pre-probiotics medications （P 〈0.05, P 〈 0.01 ）. The differences of NAFLD between before and after treatment were significant in NAFLD recovery, total plasma cholesterol, plasma triglyceride and blood urinary nitrogen of gut probiotics group （P 〈 0.05, P 〈 0.01） , but had no significance in control group （P 〉 0.05）. Conclusion The probiotics medications can prevent and treat NAFLD.